We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | NASDAQ:ALT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.20 | 3.50 | 8.10 | 7.42 | 6.90 | 7.18 | 2,250,760 | 05:00:03 |
From Apr 2019 to Apr 2024
By Chris Wack
Altimmune Inc. said Friday it expanded its previously announced AdCOVID manufacturing collaboration with Lonza.
Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune's single-dose intranasal vaccine candidate for Covid-19, at its facility near Houston.
The biopharmaceutical company said that by expanding its Lonza collaboration and commissioning its own dedicated manufacturing suite, it is building extra capacity and redundancy into its manufacturing to support potential late-stage clinical trials with AdCOVID and potential future commercial supply.
AdCOVID is a Covid-19 vaccine candidate that is administered via nasal spray. Altimmune believes that AdCOVID could provide immunity of up to a year or more following a single dose with the potential for a favorable tolerability profile. AdCOVID is expected to be shipped without cold chain logistics, permitting common refrigerated storage at community-based vaccination centers without the need for specialized freezer storage.
Altimmune's shares rose 20% to $20.06 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 12, 2021 06:29 ET (11:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Altimmune Chart |
1 Month Altimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
